Cornerstone Capital Management Holdings’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-19,798	Closed	-$192K	–	1374
2017 Q2	$192K	Buy	19,798 +5,031	+34%	+$103K	﹤0.01%	1150
2017 Q1	$357K	Buy	+14,767	New	+$369K	﹤0.01%	1101
2016 Q1	–	Sell	-178	Closed	-$11K	–	1617
2015 Q4	$11K	Sell	178 -152	-46%	-$10.7K	﹤0.01%	1424
2015 Q3	$22K	Sell	330 -788	-70%	-$64.3K	﹤0.01%	1454
2015 Q2	$109K	Buy	1,118 +343	+44%	+$32.6K	﹤0.01%	1288
2015 Q1	$72K	Buy	775 +635	+454%	+$54K	﹤0.01%	1295
2014 Q4	$12K	Buy	+140	New	+$10.2K	﹤0.01%	1241

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cornerstone Capital Management Holdings's MACK Position: Q3 2017 in Review

Cornerstone Capital Management Holdings sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 19,798 shares — an estimated $192K sold.

Cornerstone Capital Management Holdings first reported a position in MACK in Q4 2014 and held it in 7 quarters. The position peaked at $357K in Q1 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Cornerstone Capital Management Holdings reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 19,798 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $192K.
Cornerstone Capital Management Holdings first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
Cornerstone Capital Management Holdings's Merrimack Pharmaceuticals, Inc. position peaked at $357K in Q1 2017.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q3 2017, filed 14 Nov 2017.